G. Steven Burrill to Give Featured Presentation at Diabetes Summit 2013 (April 29-30 in Boston, MA)
Summary
These two Summits will provide delegates unmatched learning and networking opportunities in the following tracks, provided through our Summit Pass: 1) Stem Cell Research and Regenerative Medicine 4) Stem Cell Commercialization and Partnering 3) 6th Diabetes Drug Discovery 4) 3rd Diabetes Partnering and Deal-making For more information, please visit www.gtcbio.com/diabetes Monrovia, CA, March 14, 2013 --( PR.com )-- G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for more than 45 years.He is currently chairman of AliveCor, and serves on the boards of directors of Catalyst Biosciences, Depomed, NewBridge Pharmaceuticals, Novadaq Technologies, Targacept, and XDx.In 2002, he was recognized as a biotech investment visionary by Scientific American magazine.Diabetes Summit 2013 brings together venture capitalists, industry experts and leaders from academic institutions to cover many current and relevant aspects of diabetes.The following companies will be represented Rhythm, NIH, Novo Nordisk, Johnson and Johnson, Astra Zeneca, Thermo Fisher, Merck, Mesoblast, Zafgen, Medpace, Mannkind, Metanomics, Boston University, Harvard, Arizona State, Tufts, etc.GTC’s Diabetes Summit 2013 will run concurrently on April 29-30 in Boston, MA with Stem Cell Summit 2013.These two Summits will provide delegates unmatched learning and networking opportunities in the following tracks, provided through our Summit Pass:1) Stem Cell Research and Regenerative Medicine4) Stem Cell Commercialization and Partnering3) 6th Diabetes Drug Discovery4) 3rd Diabetes Partnering and Deal-makingFor more information, please visit www.gtcbio.com/diabetes Contact Information GTCbio Eileen Zhao 626-256-6405 http://www.gtcbio.com 635 W. Foothill Blvd.